Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression
European Archives of Psychiatry and Clinical Neuroscience · 2025-09 · 275 (6) · 1547-1557
DOI: 10.1007/s00406-024-01875-z ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Archives of Psychiatry and Clinical Neuroscience, online erschienen am 29.08.2024. Verfasst von Florian Freudenberg und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital, Goethe University Frankfurt, Heinrich-Hoffmann-Str. 10, 6052…. Hauptthemen laut MEDLINE: Ketamine, Antidepressive Agents, Excitatory Amino Acid Antagonists, Glutamic Acid. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johann Wolfgang Goethe-Universität, Frankfurt am Main.
Themen: Depression
Abstract (Originalsprache)
Changes in glutamatergic neuroplasticity has been proposed as one of the core mechanisms underlying the pathophysiology of depression. In consequence components of the glutamatergic synapse have been explored as potential targets for antidepressant treatment. The rapid antidepressant effect of the NMDA receptor antagonist ketamine and subsequent approval of its S-enantiomer (i.e. esketamine), have set the precedent for investigation into other glutamatergic rapid acting antidepressants (RAADs). In this review, we discuss the potential of the different glutamatergic targets for antidepressant treatment. We describe important clinical outcomes of several key molecules targeting components of the glutamatergic synapse and their applicability as RAADs. Specifically, here we focus on substances beyond (es)ketamine, for which meaningful data from clinical trials are available, including arketamine, esmethadone, nitrous oxide and other glutamate receptor modulators. Molecules only successful in preclinical settings and case reports/series are only marginally discussed. With this review, we aim underscore the critical role of glutamatergic modulation in advancing antidepressant therapy, thereby possibly enhancing clinical outcomes but also to reducing the burden of depression through faster therapeutic effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital, Goethe University Frankfurt, Heinrich-Hoffmann-Str. 10, 60528, Frankfurt am Main, Germany. freudenberg@em.uni-frankfurt.de.
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital, Goethe University Frankfurt, Heinrich-Hoffmann-Str. 10, 60528, Frankfurt am Main, Germany.
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Theodor-Stern-Kai 7, 60596, Frankfurt Am Main, Germany.
Förderung
- Johann Wolfgang Goethe-Universität, Frankfurt am Main
Zitieren
APA
Freudenberg, F., Reif-Leonhard, C., & Reif, A. (2025). Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression. European Archives of Psychiatry and Clinical Neuroscience, 275(6), 1547-1557. https://doi.org/10.1007/s00406-024-01875-z
Vancouver
Freudenberg F, Reif-Leonhard C, Reif A. Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression. European Archives of Psychiatry and Clinical Neuroscience. 2025;275(6):1547-1557. doi:10.1007/s00406-024-01875-z
BibTeX
@article{Freudenberg2025,
author = {Freudenberg, Florian and Reif-Leonhard, Christine and Reif, Andreas},
title = {Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression},
journal = {European Archives of Psychiatry and Clinical Neuroscience},
year = {2025},
volume = {275},
number = {6},
pages = {1547--1557},
doi = {10.1007/s00406-024-01875-z}
}
EUVIMED